Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.
Ocul Immunol Inflamm
; 31(10): 1997-2000, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-36657742
ABSTRACT
AIM:
To describe the efficacy and safety of subcutaneous tocilizumab (SC-TCZ) in a cohort of juvenile idiopathic arthritis (JIA) patients with refractory uveitis.METHODS:
Retrospective observational monocentric study including patients with JIA-associated uveitis treated with SC-TCZ.RESULTS:
Thirteen patients were enrolled. The rate of uveitis flare/year per each patient was 1.6 ± 2.0 on the last bDMARDs before SC-TCZ, while it decreased to 0.4 ± 0.7 on SC-TCZ. Nine out of thirteen patients (69%) required the introduction of SC-TCZ only for active uveitis at baseline. Among these patients, five (56%) achieved complete treatment response. No uveitis relapses were observed in patients (4/13, 31%) requiring the introduction of SC-TCZ for active arthritis during follow-up (30.48 ± 21.6 months). Overall, SC-TCZ was safe, and no side effects were observed during the treatment.CONCLUSION:
SC-TCZ can be effective and safe in patients with JIA and uveitis recalcitrant to several bDMARDs.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Juvenile
/
Uveitis
/
Antirheumatic Agents
Type of study:
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Ocul Immunol Inflamm
Journal subject:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Year:
2023
Document type:
Article
Affiliation country: